164 related articles for article (PubMed ID: 10468849)
61. Detection of DNA double-strand breaks and chromosome translocations using ligation-mediated PCR and inverse PCR.
Villalobos MJ; Betti CJ; Vaughan AT
Methods Mol Biol; 2005; 291():279-89. PubMed ID: 15502230
[TBL] [Abstract][Full Text] [Related]
62. Monozygotic twins with non-Down syndrome associated MLL-rearranged hematologic malignancy and megakaryoblastic differentiation.
Foster JH; Williams CL; Elghetany MT; Liu P; Krance RA; Bertuch AA; Gramatges MM
Leuk Lymphoma; 2019 Apr; 60(4):1083-1086. PubMed ID: 30277109
[No Abstract] [Full Text] [Related]
63. Controlling false positive rates in prognostic factor analyses with small samples.
Liu Q; Li Y; Boyett JM
Stat Med; 1997 Sep; 16(18):2095-101. PubMed ID: 9308134
[TBL] [Abstract][Full Text] [Related]
64. [GMP synthetase].
Yamaoka T
Nihon Rinsho; 2003 Jan; 61 Suppl 1():66-70. PubMed ID: 12629692
[No Abstract] [Full Text] [Related]
65. New insights into molecular mechanisms of haematological malignancies.
Fey MF
Ann Oncol; 2008 Jul; 19 Suppl 5():v59-62. PubMed ID: 18611902
[No Abstract] [Full Text] [Related]
66. Translocations in epithelial cancers.
Brenner JC; Chinnaiyan AM
Biochim Biophys Acta; 2009 Dec; 1796(2):201-15. PubMed ID: 19406209
[TBL] [Abstract][Full Text] [Related]
67. An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners.
Huret JL; Dessen P; Bernheim A
Leukemia; 2001 Jun; 15(6):987-9. PubMed ID: 11417488
[No Abstract] [Full Text] [Related]
68. [Hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities: report of three cases and literature review].
Fu HX; Gu YQ; Lai YY; Qin YZ; Wang JZ; Chen H; Xu LP; Zhang XH; Liu KY; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):937-940. PubMed ID: 33333698
[No Abstract] [Full Text] [Related]
69. 154 chromosome anomalies in hematologic malignancies.
Dewald GW; Stupca P
Leuk Res; 2000 Jun; 24(6):487-9. PubMed ID: 10781682
[No Abstract] [Full Text] [Related]
70. Chromosomal assessment of haematological malignancies: Flow-FISHing for genetic abnormalities.
Fuller KA
Pathology; 2024 Aug; 56(5):617-618. PubMed ID: 38862379
[No Abstract] [Full Text] [Related]
71. [Molecular biology: generality].
Bastard C
Pathol Biol (Paris); 2003 Aug; 51(6):312-3. PubMed ID: 12927888
[TBL] [Abstract][Full Text] [Related]
72. Regions of juxtaposition in unbalanced 1q rearrangements of malignant hemopathies.
La Starza R; Aventin A; Falzetti D; Wlodarska I; Fernandez Peralta AM; Gonzalez-Aguilera JJ; Ciolli S; Martelli MF; Mecucci C
Leukemia; 2001 May; 15(5):861-3. PubMed ID: 11368453
[No Abstract] [Full Text] [Related]
73. Hematolymphoid neoplasms with a plasma cell phenotype.
Rosado F; Guo L; Fuda F
Semin Diagn Pathol; 2020 Nov; 37(6):268-272. PubMed ID: 32564903
[No Abstract] [Full Text] [Related]
74. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
Klaus CR; Iwanowicz D; Johnston D; Campbell CA; Smith JJ; Moyer MP; Copeland RA; Olhava EJ; Scott MP; Pollock RM; Daigle SR; Raimondi A
J Pharmacol Exp Ther; 2014 Sep; 350(3):646-56. PubMed ID: 24993360
[TBL] [Abstract][Full Text] [Related]
75. FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia.
Dobish KK; Wittorf KJ; Swenson SA; Bean DC; Gavile CM; Woods NT; Ghosal G; Hyde RK; Buckley SM
Leukemia; 2023 Nov; 37(11):2197-2208. PubMed ID: 37689825
[TBL] [Abstract][Full Text] [Related]
76. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Numata M; Haginoya N; Shiroishi M; Hirata T; Sato-Otsubo A; Yoshikawa K; Takata Y; Nagase R; Kashimoto Y; Suzuki M; Schulte N; Polier G; Kurimoto A; Tomoe Y; Toyota A; Yoneyama T; Imai E; Watanabe K; Hamada T; Kanada R; Watanabe J; Kagoshima Y; Tokumaru E; Murata K; Baba T; Shinozaki T; Ohtsuka M; Goto K; Karibe T; Deguchi T; Gocho Y; Yoshida M; Tomizawa D; Kato M; Tsutsumi S; Kitagawa M; Abe Y
Cancer Cell Int; 2023 Feb; 23(1):36. PubMed ID: 36841758
[TBL] [Abstract][Full Text] [Related]
77. Advances in the pharmacological management of acute myeloid leukemia in adults.
Numan Y; Abaza Y; Altman JK; Platanias LC
Expert Opin Pharmacother; 2022 Sep; 23(13):1535-1543. PubMed ID: 35938317
[TBL] [Abstract][Full Text] [Related]
78. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
Zhang M; Aguilar A; Xu S; Huang L; Chinnaswamy K; Sleger T; Wang B; Gross S; Nicolay BN; Ronseaux S; Harvey K; Wang Y; McEachern D; Kirchhoff PD; Liu Z; Stuckey J; Tron AE; Liu T; Wang S
J Med Chem; 2021 Jul; 64(14):10333-10349. PubMed ID: 34196551
[TBL] [Abstract][Full Text] [Related]
79. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
80. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S; Miao H; Kempinska K; Wu T; Purohit T; Kim E; Linhares BM; Chen D; Jih G; Perkey E; Huang H; He M; Wen B; Wang Y; Yu K; Lee SC; Danet-Desnoyers G; Trotman W; Kandarpa M; Cotton A; Abdel-Wahab O; Lei H; Dou Y; Guzman M; Peterson L; Gruber T; Choi S; Sun D; Ren P; Li LS; Liu Y; Burrows F; Maillard I; Cierpicki T; Grembecka J
J Clin Invest; 2020 Feb; 130(2):981-997. PubMed ID: 31855575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
